


4th Annual

Ophthalmology Times

Research Scholar

Honoree Program

2020



November 5, 2020 — Virtual Program

This medical education program is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Learning Method and Medium

This educational activity consists of research, abstract submissions, live presentations, and enduring article distribution.

This is a non-accredited educational activity.

Activity Description

This activity uses an expert panel of judges to provide insight and feedback to fellows and residents on research abstracts, live presentations, and what the research contributes to the retinal community.

Target Audience

This educational activity is intended for retina fellows and residents.

Disclosures

Thomas A. Albin, MD has a financial agreement or affiliation during the past year with the following commercial interests in the form of:

Consultant: Abbvie, Alcon Pharmaceuticals, Allergan, Clearside, Genentech, Mallinckrodt, Novartis, pSivida, and Santen, Inc.

Mark S. Blumenkranz, MD, MMS has a financial agreement or affiliation during the past year with the following commercial interests in the form of:

Equity: BVI Visitec, Combango Corporation, Iveric bio, Kedalion Therapeutics, Lagunita Biosciences, One Medical, and Verana Health

Seenu M. Hariprasad, MD has a financial agreement or affiliation during the past year with the following commercial interests in the form of:

Consultant: Alimera Sciences, Allergan, Bausch & Lomb, EyePoint, Graybug, Novartis, OD-OS, Spark, and Regeneron

Jonathan L. Prener, MD has a financial agreement or

Learning Objectives

Upon completion of this program, participants will be better able to:

- Recognize unique and notable research in the area of retinal disease;
- Identify areas of emerging treatment options;
- Apply new information acquired to improve patient outcomes.

Grantor Statement

This educational activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

affiliation during the past year with the following commercial interests in the form of:

Consultant: Alcon, Novartis, and Regeneron

Rishi P. Singh, MD has a financial agreement or affiliation during the past year with the following commercial interests in the form of:

Consultant: Alcon, Bausch and Lomb, Genentech, Novartis, Optos, Regeneron, and Zeiss

Research Support: Apellis

Ophthalmology Times[®] Editorial Support Disclosures

Peter J. McDonnell, MD has a financial agreement or affiliation during the past year with the following commercial interests in the form of:

Board of Directors: Aerie Pharmaceuticals, Inc.

Sheryl Stevenson has no relevant commercial relationships.

Michelle Dalton, ELS has no relevant commercial relationships.

About the Program

This program is dedicated to the education of fellows and residents and offers a unique opportunity to share notable retina research with peers and mentors. This program is supported by an unrestricted grant from Regeneron Pharmaceuticals.

Program Description

Ophthalmology Times[®] requested ophthalmic institutions to nominate fellows and residents involved in unique/ notable research in retinal disease. Qualifying fellows and residents have been asked to submit an abstract, a short summary, and a presentation to include what the research contributes to the retinal community. All submissions have been reviewed by a panel of expert judges, and

the top research submissions have been invited to present in a live virtual event. Today's presentations and feedback provided by our expert panel of judges, promises to provide all attendees with a rich educational experience.

Opening the awards portion of the day will be a keynote address given by Mark S. Blumenkranz, MD, MMS. At the conclusion of today, the Top 5 Finalists will be selected and will be featured in a peer-reviewed supplement in 2021. To make this valuable education available to a broader audience, all of those selected to present here today will be published online within ophthalmology-times.com and the top 5 summaries will be featured in an edition of *Ophthalmology Times*[®].

**Peter J. McDonnell, MD**

Director of The Wilmer Eye Institute;
William Holland Wilmer Professor of Ophthalmology;
Chief Medical Editor, *Ophthalmology Times*

**Sheryl Stevenson**

Group Editorial Director,
MJH Life Sciences,
Ophthalmology Times



Rishi P. Singh, MD (Program Chair) is a staff surgeon at the Cole Eye Institute, Cleveland Clinic and Associate Professor of Ophthalmology at the Lerner College of Medicine in Cleveland, OH. He also currently serves as the medical director of informatics at the Cleveland Clinic. He received his bachelors and medical degrees from Boston University and completed his residency at the Massachusetts Eye and Ear Infirmary Harvard Combined Program in Boston, Massachusetts. Dr. Singh then completed a medical and surgical fellowship at the Cole Eye Institute in Cleveland, OH.

He specializes in the treatment of medical and surgical retinal disease such as diabetic retinopathy, retinal detachment, and age-related macular degeneration. Dr. Singh has authored greater than 160 peer reviewed publications, books, and book chapters and serves as the principal investigator of numerous national clinical trials advancing the treatment of retinal disease. He is frequently invited to speak at national and international meetings, as well as continuing medical education seminars.

Dr. Singh is the current president on the Retina World Congress and is on the board of the American Society of Retina Specialists. Dr. Singh is the associate editor of *Ophthalmic Surgery, Lasers and Imaging Retina Journal (OSLI-Retina)* and is the editor of the *American Journal of Ophthalmic Clinical Trials*. He maintains a strong relationship with drug development and commercial entities by serving on scientific advisory boards.

Dr. Singh's current work focuses on electronic medical records implementation, big data analyses, machine learning, lean process improvement, and decision support modules for clinical practice. Dr. Singh has been honored with several research recognitions such as the Alpha Omega Alpha Research Award, American Society of Retina Specialists Senior Honor Award, and the American Society of Retina Specialists Young Investigator Award.

Dr. Singh received a Bachelor of Arts degree, Magna Cum Laude, from Princeton University and a Doctor of Medicine degree from Johns Hopkins University School of Medicine. He completed an ophthalmology residency at Doheny Eye Institute of the University of Southern California. He then completed a uveitis clinical and research fellowship at Doheny Eye Institute and a vitreoretinal surgery fellowship at Cullen Eye Institute of the



Thomas A. Albini, MD received a Bachelor of Arts degree, Magna Cum Laude, from Princeton University and a Doctor of Medicine degree from Johns Hopkins University School of Medicine. He completed an ophthalmology residency at Doheny Eye Institute of the University of Southern California. He then completed a uveitis clinical and research fellowship at Doheny Eye Institute and a vitreoretinal surgery fellowship at Cullen Eye Institute of the

Baylor College of Medicine. Dr. Albini currently is Professor of Clinical Ophthalmology at the Bascom Palmer Eye Institute in Miami, FL and serves as director of the vitreoretinal surgery fellowship. His research interests include treatment and diagnosis of uveitis and macular disorders. He has recently published multiple papers on the risks of alternative, unproven "stem cell" therapies for eye disorders, leading to significant changes in US federal policy. He is a member of numerous professional and honorary societies, including the American Academy of Ophthalmology, the American Society of Retina Specialists, The Retina Society, the Macula Society, the Club Jules Gonin, the American Uveitis Society and the International Uveitis Study Group. He served as president of the Vit-Buckle Society. He also served as Editor-in-Chief of the American Society of Retina Specialists' web site for 4 years. Dr. Albini has received numerous awards including an Achievement Award from the American Academy of Ophthalmology and a Senior Achievement Award from the American Society of Retina Specialists. He has authored over 130 peer-reviewed articles on clinical and experimental topics in vitreoretinal disease and uveitis.

**Mark S. Blumenkranz, MD, MMS**

is a co-founder and the Chairman and CEO of Kedalion Therapeutics a clinical stage ophthalmic pharmaceutical company. He is also the Managing Director of Lagunita Biosciences an early stage healthcare investment company and incubator in Menlo Park CA and HJ Smead Professor Emeritus in the Department of Ophthalmology at Stanford University where he is the Founder and Co-Director of the Ophthalmic Innovation Program. He served as the Chairman of the Department of Ophthalmology from 1997 until 2015 and played a leading role in the planning, fundraising and construction of the Byers Eye Institute at Stanford. He is a past President of the American University Professors of Ophthalmology (AUPO), the Retina Society and the Macula Society and is a Fellow Emeritus of the Corporation of Brown University where he chaired the Medical School Committee (2002-2019). He is a member of the steering committee of the National Eye Institute's Audacious Goals Initiative, the founding Convener of the Collaborative Community on Ophthalmic Imaging (CCOI) and was a member of the Board of Trustees of the Jackson Laboratory from 2017 to 2020. He is a co-founder and also serves as a director of Verana Health and is a member of the board of Directors of BVI Visitec, Combangio, Iveric, (ISEE:NASDAQ) and One Medical (ONEM:NASDAQ).



Seenu M. Hariprasad, MD, Interim Chair and Professor in the Department of Ophthalmology and Visual Science at the University of Chicago, has been named the department's first Shui-Chin Lee Professor. Dr. Hariprasad is an internationally

recognized expert in the diseases and surgery of the retina, vitreous, and macula. He is an active leader in the Department of Ophthalmology and Visual Science, serving as Chief of the Vitreoretinal Service, Director of Clinical Research, and Director of the Fellowship in Vitreoretinal Diseases and Surgery. Since joining the University of Chicago in 2005, Dr. Hariprasad has gained a reputation as a leading specialist in various vitreoretinal disorders, including AMD, diabetic eye disease, intraocular infection and RVO. He has been recognized for bringing more effective and efficient sutureless microincisional vitrectomy techniques to the University of Chicago. Dr. Hariprasad's clinical research has contributed to the understanding and use of new medications to combat a wide variety of vitreoretinal disorders. He has served as principal or sub-investigator in more than 45 national and international clinical trials evaluating various medications, sustained drug-delivery devices and surgical innovations to treat a variety of diseases, such as AMD, diabetic retinopathy and RVO. His work has led to over 300 peer-reviewed publications, meeting abstracts and textbook chapters. He has presented more than 150 individual lectures in

cities around the world. Dr. Hariprasad's recently published textbook, *Management of Retinal Vein Occlusion: Current Concepts*, is one of only a small number of textbooks dedicated to this disease. He has also been awarded numerous honors, including an AAO Achievement Award and an ASRS Honor Achievement Award, and has been named a top doctor in publications such as *US News & World Report* and *Chicago Magazine*.



Jonathan L. Prenner, MD is Chairman of the Department of Ophthalmology at Rutgers Robert Wood Johnson Medical School where he serves as Clinical Professor. Dr. Prenner is the Treasurer for and a member of the ASRS Executive Committee. For the

past decade, he has held the positions of Assistant Editor and Review Article Section Editor for the standard scientific journal for the field, *RETINA: The Journal of Retinal and Vitreous Diseases*. Dr. Prenner has published more than 85 papers in the peer-reviewed literature in addition to a volume of textbook chapters, articles and scientific abstracts. He has been elected by his peers for inclusion in *Best Doctors in America* since 2008 and is listed as a *U.S. News and Castle Connolly* best doctor and as one of *New York Magazine's* Best Doctors. He has been elected to the *Retina Hall of Fame* and the *OSN 150*.



Agenda — Presentation Schedule

Time		
3:00pm	Welcome & Introductions	Sheryl Stevenson, Ophthalmology Times Group Editorial Director
3:05pm	Program Overview & Introduction of Judges	Rishi P. Singh, MD—Program Chair Staff Physician, Cole Eye Institute, Cleveland Clinic Foundation Associate Professor of Ophthalmology, Lerner College of Medicine, Case Western Reserve University
3:10pm	Presentations	
3:10pm	<i>Early visual functions deficiency and OCT-A changes at the preclinical stage of diabetic retinopathy: a prospective study</i>	 Anna Stulova, MD Fellow Ophthalmology Department, Faculty of Medicine Lomonosov Moscow State University
3:20pm	<i>Clinical OCT Imaging of Immune cells in Living Human Eyes with Diabetic Retinopathy</i>	 Maria V. Castanos, MD Resident New York Eye and Ear Infirmary of Mount Sinai New York, NY
3:30pm	<i>Risk Factors of Ischemic Cerebral Stroke in Patients Presenting with Amaurosis Fugax</i>	 Tony Y. Chen, MD, MA Resident Rutgers - New Jersey Medical School Newark, NJ
3:40pm	<i>Proteomic Comparison of Vitreous Samples from Diabetic and Control Patients</i>	 Christopher John Davis, MD Resident Kresge Eye Institute Wayne State University Detroit, MI
3:50pm	<i>Significance of Early Outer Retinal Findings on En Face and Cross-Sectional Optical Coherence Tomography Imaging of Eyes with Macula-Off Rhegmatogenous Retinal Detachment</i>	 Tina Felfeli, MD Resident University of Toronto Toronto, Ontario
4:00pm	Break	
4:15pm	<i>Incidence and Risk Factors for the Development of Treatment-Warranted Diabetic Macular Edema at 5 Years Following Initial Diagnosis of Type 2 Diabetes</i>	 William Gange, MD Resident USC Roski Eye Institute Los Angeles, CA

Agenda — Presentation Schedule

Time		
4:25pm	<i>Fixation distance formula for scleral fixated intraocular lenses</i>	 Jae Kim, MD Resident Kresge Eye Institute Wayne State University Detroit, MI
4:35pm	<i>The Proteome of Proliferative Vitreoretinopathy: New insight into the central role of extracellular matrix</i>	 Charles G. Miller, MD, PhD Fellow Scheie Eye Institute University of Pennsylvania Philadelphia, PA
4:45pm	<i>Intravitreal injections and endophthalmitis: Does lidocaine gel change the risk of the infection?</i>	 Jamie Odden, MD, MPH Resident University of Pittsburgh Medical Center Pittsburgh, PA
4:55pm	<i>The impact of systemic immunosuppression on endophthalmitis after intravitreal anti-VEGF injections</i>	 Samir N. Patel, MD Vitreoretinal Fellow Wills Eye Hospital Mid Atlantic Retina Philadelphia, PA
5:05pm	Break	
5:25pm	<i>Correlation of Retinal Thickness and Perfusion Metrics with Renal Function in Sickle Cell Retinopathy Using Optical Coherence Tomography (OCT) and OCT-Angiography</i>	 Kareem Sioufi, MD Resident Storm Eye MUSC Charleston, SC
5:35pm	<i>Fundus Autofluorescence Patterns Before and After Treatment for Primary Vitreoretinal Lymphoma</i>	 Ethan K. Sobol, MD Resident, PGY4 Icahn School of Medicine at Mount Sinai New York, NY
5:45pm	<i>Systemic Medication Use with the Incidence and Growth of Geographic Atrophy</i>	 Delu Song, MD, PhD, MTR Resident Scheie Eye Institute University of Pennsylvania Philadelphia, PA

Agenda — Presentation Schedule

Time		
5:55pm	<i>Application of Active Learning of the Contrast Sensitivity Function in Patients with Macular Disease and Good Visual Acuity</i>	 Karen M. Wai, MD Resident Massachusetts Eye and Ear Infirmary Boston, MA
6:05pm	<i>A Computational Model of Choroideremia</i>	 Benjamin K. Young, MD, MS Resident Graduate Yale University School of Medicine New Haven, CT First Year Vitreoretinal Surgery Fellow Kellogg Eye Center, University of Michigan Ann Arbor, MI
6:15pm	Break	
6:20pm	Keynote Speaker	Mark S. Blumenkranz MD, MMS H. J. Smead Professor of Ophthalmology, Emeritus Byers Eye Institute at Stanford Co-Director Ophthalmology Innovation Program
6:45pm	Awards Presentation Top 5 » 5th Place Finalist » 4th Place Finalist » 3rd Place Finalist » 2nd Place Finalist » 1st Place Winner	Rishi P. Singh, MD
7:00pm	Program Concludes	

Ophthalmology Times[®]

AN **MH** life sciences[™] BRAND

Ophthalmology Times[®] wishes to thank the sponsor of this program, our expert panel of judges, and the participants of the 2020 Ophthalmology Times[®] Research Scholar Honoree program.

REGENERON